New Alzheimer's drug candidate enters first human safety tests

NCT ID NCT07690228

Not yet recruiting Disease control Sponsor: Acta Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study tests the safety and tolerability of a new drug called GSM-779690T, which is being developed for Alzheimer's disease. It involves 72 healthy adults aged 18 to 55 who will receive either the drug or a placebo. Researchers will monitor for side effects and measure how the drug moves through the body. This is the first time the drug is being tested in humans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GSM-779690T
What this could lead to: If safe and effective in later trials, GSM-779690T could become a new treatment to slow or control Alzheimer's disease.
What could go wrong: This is a very early, small study in healthy people, not Alzheimer's patients. The drug may prove unsafe or ineffective in later stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE HEALTHY ADULT PARTICIPANTS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Nucleus Network Pty Ltd

Melbourne, Victoria, 3004, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.